{
    "clinical_study": {
        "@rank": "6529", 
        "brief_summary": {
            "textblock": "Phase 2 clinical trial to evaluate the safety and efficacy of IPI-145 as a monotherapy in\n      subjects with iNHL (FL, MZL, or SLL) that is refractory to a rituximab containing\n      chemotherapy regimen or RIT."
        }, 
        "brief_title": "A Phase 2 Study of IPI-145 in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)", 
        "completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Indolent Non-Hodgkin Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, single arm safety and efficacy study of IPI-145 administered orally\n      to subjects who have been diagnosed with iNHL (FL, MZL, or SLL) whose disease is refractory\n      to rituximab and chemotherapy in combination or RIT.\n\n      Approximately 120 subjects will receive 25 mg IPI-145 BID over the course of 28-day\n      treatment cycles for up to 12 cycles.\n\n      After completing 12 treatment cycles of IPI-145, subjects may continue to receive additional\n      cycles of IPI-145 for up to a total of 2 years of treatment.  However, to receive additional\n      cycles of IPI-145 beyond 12 cycles, subjects must have evidence of response (CR or PR)\n      according to the IWG criteria1 by the end of Cycle 12."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who have been diagnosed with indolent NHL  that has progressed.\n\n          -  Subjects must have exhibited no response or progression within 6 months after the\n             last dose of a chemotherapy induction regimen or RIT.\n\n          -  Subjects must have rituximab-refractory disease.\n\n          -  Measurable disease with a lymph node or tumor mass \u22651.5 cm in at least one dimension\n             by CT.\n\n          -  Adequate renal and hepatic function.\n\n        Exclusion Criteria:\n\n          -  Candidate for potentially curative therapies in the opinion of the investigator.\n\n          -  Previous treatment with a PI3K inhibitor within 30 days of starting IPI-145 therapy.\n\n          -  Prior history of allogeneic hematopoietic stem cell transplant (HSCT).\n\n          -  Prior chemotherapy, cancer immunosuppressive therapy, or other investigational agents\n             within 3 weeks before first dose of study drug.\n\n          -  Grade 3B FL and/or clinical evidence of transformation to a more aggressive subtype\n             of lymphoma.\n\n          -  Symptomatic central nervous system (CNS) NHL.\n\n          -  Ongoing systemic bacterial, fungal, or viral infections at the time of initiation of\n             study treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01882803", 
            "org_study_id": "IPI-145-06"
        }, 
        "intervention": {
            "description": "PI3K Inhibitor", 
            "intervention_name": "IPI-145", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "PI3K Inhibitor", 
        "lastchanged_date": "March 31, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Mobile", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Myers", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pensacola", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tallahassee", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Thomasville", 
                        "country": "United States", 
                        "state": "Georgia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morristown", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lawton", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Watertown", 
                        "country": "United States", 
                        "state": "South Dakota"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lynchburg", 
                        "country": "United States", 
                        "state": "Virginia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Study of IPI-145 in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)", 
        "overall_contact": {
            "email": "karen.bracken@infi.com", 
            "last_name": "Karen Bracken", 
            "phone": "704-875-3677"
        }, 
        "overall_official": {
            "affiliation": "Infinity Pharmaceuticals, Inc.", 
            "last_name": "Patrick Kelly, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Objective response rate (ORR) in all subjects during treatment with IPI-145 based on standard response.", 
            "safety_issue": "No", 
            "time_frame": "Every 8-16 weeks while on treatment with IPI-145; an expected average on-treatment duration of response follow-up of 20 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01882803"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of drug-related (at least possibly) adverse events; Number of serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Every 2-8 weeks; up to 30 days after the last dose of IPI-145"
            }, 
            {
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "Every 8-16 weeks; for an average duration of response follow-up of 24 months"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Every 8-16 weeks; for an average response / progression follow-up of 24 months"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Every 16 weeks; for an average survival follow-up of 24 months"
            }, 
            {
                "measure": "Plasma concentrations of IPI-145 and its metabolite(s)", 
                "safety_issue": "No", 
                "time_frame": "Every 4 weeks for 12 weeks"
            }
        ], 
        "source": "Infinity Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Infinity Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}